Targeted Biologic Therapies Will Serve An Aging World
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
06 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$30.00
49.7% undervalued intrinsic discount21 Aug
US$15.10
1Y
32.6%7D
5.2%